The development of new immunotherapies for treatment-resistant cancer

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K24035
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0906:Surgery related to the biological and sensory functions and related fields
• Research Institution: Osaka City University
• Principal Investigator: Yamaguchi Kazuyuki 大阪市立大学, 大学院医学研究科, 医員 (80848317)
• Project Period (FY): 2019-08-30 – 2021-03-31
• Keywords: 癌 / マクロファージ / PHD阻害薬

Outline of Final Research Achievements

The mice of HIF-1, HIF-2 deficient and/or HIF-1, HIF-2 overexpressing in Mφ are prepared. The impact of them was examined. By performing tumor growth curve, phagocytosis assay, flow cytometry, etc., it was clarified that HIF-1 and HIF-2 in Mφ are effected in tumor growth. We have identified a factor that may be involved in tumor suppression, and in the future we plan to clarify the detailed mechanism of how blocking and administering this factor is involved in tumor growth suppression.

Free Research Field

泌尿器病態学

Academic Significance and Societal Importance of the Research Achievements

HIFを介して腫瘍内Mφが活性化する機能を明らかにするとともに、腫瘍内Mφ活性化に関与する分子を同定することで新規抗悪性腫瘍薬の創出につながると期待される。